Pharmaceutical

Carmot’s chance of beating the odds in the biotech market just ended

Carmot’s chance of beating the odds in the biotech mark...

Dec 5, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

Aficamten by Cytokinetics for Diastolic Heart Failure (...

Dec 4, 2023

Aficamten is under clinical development by Cytokinetics and currently in Phase I...

TTI-101 by Tvardi Therapeutics for Head And Neck Squamo...

Dec 4, 2023

TTI-101 is under clinical development by Tvardi Therapeutics and currently in Ph...

Ketamine ER by Douglas Pharmaceuticals for Major Depres...

Dec 4, 2023

Ketamine ER is under clinical development by Douglas Pharmaceuticals and current...

SIM-325 by TCR Cure Biopharma Technology for Head And N...

Dec 4, 2023

SIM-325 is under clinical development by TCR Cure Biopharma Technology and curre...

Latozinemab by Alector for Frontotemporal Dementia (FTD): Likelihood of Approval

Latozinemab by Alector for Frontotemporal Dementia (FTD...

Dec 4, 2023

Latozinemab is under clinical development by Alector and currently in Phase III ...

SGN-1 by Guangzhou Sinogen Pharmaceutical for Head And ...

Dec 4, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and curr...

RiMO-301 by Rimo Therapeutics for Recurrent Head And Ne...

Dec 4, 2023

RiMO-301 is under clinical development by Rimo Therapeutics and currently in Pha...

AZ-3102 by Azafaros for Niemann-Pick Disease Type C: Li...

Dec 4, 2023

AZ-3102 is under clinical development by Azafaros and currently in Phase II for ...

J-2H1702 by J2H Biotech for Metabolic Dysfunction-Assoc...

Dec 4, 2023

J-2H1702 is under clinical development by J2H Biotech and currently in Phase II ...

NN-9440 by Inversago Pharma for Metabolic Syndrome: Lik...

Dec 4, 2023

NN-9440 is under clinical development by Inversago Pharma and currently in Phase...

Opinion: STAT readers on burnt-out infectious disease doctors, 12-month prescriptions, and counting disabled Americans

Opinion: STAT readers on burnt-out infectious disease d...

Dec 3, 2023

Letters to the editor: “It's no wonder that ID doctors are some of the most burn...

STAT+: Takeda, Janssen join wearable maker to measure scratching, and other health tech news

STAT+: Takeda, Janssen join wearable maker to measure s...

Dec 3, 2023

In the latest edition of Health Tech newsletter: Takeda, Janssen team up with Ac...

STAT+: Do GLP-1s have a future treating alcoholism?

STAT+: Do GLP-1s have a future treating alcoholism?

Dec 3, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

Navigating affordable approaches to cell therapy clinical trials

Navigating affordable approaches to cell therapy clinic...

Dec 2, 2023

By Luisa Sterkel & Joana Loureiro, Tenthpin Consultants and Dr. Frank Altznauer...

Biocon integrates Viatris biosimilars in 31 European countries

Biocon integrates Viatris biosimilars in 31 European co...

Dec 2, 2023

Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimi...